1 / 1

Impact of DEAB Inhibition on Trastuzumab Treatment Efficacy in HER2-Positive Breast Cancer Models

This study investigates the effects of DEAB inhibition on the response of various HER2-positive breast cancer cell lines, including MDA-MB-453, JIMT-1, and Sum159-HER2, when treated with trastuzumab compared to control treatments. The results indicate significant differences in ALDH1 expression levels, suggesting the role of ALDH1 in cancer stem cell dynamics and treatment resistance. Supplemental data including figures illustrate the varying responses of these cell lines to the treatments, contributing to the understanding of therapeutic strategies in HER2-positive breast cancer.

bisa
Download Presentation

Impact of DEAB Inhibition on Trastuzumab Treatment Efficacy in HER2-Positive Breast Cancer Models

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trastuzumab-treated Control-treated A MDA-MB-453 14.2% 10.7% DEAB-inhibited DEAB-inhibited B JIMT-1 5.2% 5.4% DEAB-inhibited DEAB-inhibited C Sum159-HER2 7.1% 36% DEAB-inhibited DEAB-inhibited Trastuzumab-treated Control-treated D Supplemental Figure 5 -ALDH1-antibody

More Related